
Evotec AG (NASDAQ:EVO – Free Report) – HC Wainwright boosted their FY2026 earnings per share estimates for shares of Evotec in a note issued to investors on Friday, November 6th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of ($0.75) per share for the year, up from their prior estimate of ($0.83). HC Wainwright has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Evotec’s Q4 2026 earnings at ($0.13) EPS.
Several other research firms also recently weighed in on EVO. Weiss Ratings downgraded shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. TD Cowen lowered shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research report on Wednesday, July 15th. Finally, Berenberg Bank cut shares of Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Evotec currently has an average rating of “Hold” and an average price target of $3.50.
Evotec Price Performance
NASDAQ EVO opened at $1.69 on Tuesday. Evotec has a 52 week low of $1.33 and a 52 week high of $3.87. The company has a quick ratio of 2.19, a current ratio of 2.32 and a debt-to-equity ratio of 0.65. The firm’s 50-day simple moving average is $1.61 and its two-hundred day simple moving average is $2.45.
Institutional Trading of Evotec
A hedge fund recently raised its stake in Evotec stock. WCM Investment Management LLC boosted its position in Evotec AG (NASDAQ:EVO – Free Report) by 12.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 627,260 shares of the company’s stock after purchasing an additional 67,917 shares during the quarter. WCM Investment Management LLC owned about 0.18% of Evotec worth $1,480,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 5.81% of the stock is owned by institutional investors and hedge funds.
Evotec Company Profile
Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Its work spans early-stage research through preclinical and clinical development, using expertise in areas such as biology, chemistry and data-driven drug discovery. The company supports programs across multiple therapeutic areas and develops both small-molecule and biologic medicines. Its Just-Evotec Biologics business focuses on the development and production of biologics, including services intended to help partners advance treatments from research toward clinical and commercial use.
Read More
- Five stocks we like better than Evotec
- Keeping AI Cool: AAON Rides the AI Heatwave to Record Growth
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
